Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Cenrifki (tolebrutinib) — Sanofi Winthrop Industrie
Cenrifki (tolebrutinib) has been authorised by the EMA for therapeutic use in multiple sclerosis, including chronic progressive forms.
-
EMA approval · 2026-08-20EMA Authorised: Ocrevus (ocrelizumab) — Roche Registration GmbH
EMA has authorised Ocrevus (ocrelizumab) by Roche Registration GmbH for therapeutic use in multiple sclerosis.
-
EMA approval · 2026-08-20EMA Authorised: Kesimpta (ofatumumab) — Novartis Europharm Limited
Authorised status for Kesimpta (ofatumumab) in relapsing-remitting multiple sclerosis in the EU.
-
EMA approval · 2026-08-11EMA Authorised: Tecfidera (dimethyl fumarate) — Biogen Netherlands B.V.
Authorisation of Tecfidera (dimethyl fumarate) in the European Union for the treatment of multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2026-08-07Clinical Trial Results: Feasibility of Remote Exercise Training for Hispanics/Latinos With MS [NA]
Feasibility study results for remotely delivered exercise training in Hispanics/Latinos with multiple sclerosis; terminated with results pos…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-08-06EMA Authorised: Vumerity (Diroximel fumarate (BIIB098)) — Biogen Netherlands B.V.
EMA has authorised Vumerity (diroximel fumarate) for relapsing-remitting multiple sclerosis, expanding Biogen's portfolio in this indication…
-
CLINICAL_TRIALS trial_result · 2026-08-05Clinical Trial Results: A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS [Phase 3]
A Phase 3 study evaluating monthly long-acting GA Depot injections for efficacy, safety, and tolerability in relapsing-remitting multiple sc…
-
EMA approval · 2026-07-30EMA Authorised: Gilenya (fingolimod hydrochloride) — Novartis Europharm Limited
Gilenya (fingolimod hydrochloride) has been authorised for use in the European Union for multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2026-07-28Clinical Trial Results: Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis [Phase 4]
Phase 4 clinical trial evaluating the impact of cladribine tablets on central nervous system biomarkers in multiple sclerosis.
-
EMA approval · 2026-07-22EMA Authorised: Dimethyl fumarate Mylan (dimethyl fumarate) — Mylan Pharmaceuticals Limited
Dimethyl fumarate Mylan has been authorised for use in the European Union as a treatment for multiple sclerosis.
-
EMA approval · 2026-07-06EMA Authorised: Tysabri (natalizumab) — Biogen Netherlands B.V.
European Medicines Agency authorises Tysabri (natalizumab) for multiple sclerosis.
-
EMA approval · 2026-07-03EMA Authorised: Kesimpta (ofatumumab) — Novartis Europharm Limited
Kesimpta (ofatumumab) has been authorised in the EU for Relapsing-Remitting Multiple Sclerosis.
-
EMA approval · 2026-06-25EMA Authorised: Cenrifki (tolebrutinib) — Sanofi Winthrop Industrie
Cenrifki (tolebrutinib) has been authorised in the EU for multiple sclerosis, including chronic progressive forms.
-
EMA approval · 2026-06-12EMA Authorised: Dimethyl fumarate Mylan (dimethyl fumarate) — Mylan Pharmaceuticals Limited
Dimethyl fumarate by Mylan Pharmaceuticals Limited has been authorised for multiple sclerosis in the EU.
-
EMA approval · 2026-06-11EMA Authorised: Teriflunomide Viatris (previously Teriflunomide Mylan) (teriflunomide) — Viatris Limited
Teriflunomide Viatris has been authorised in the EU for relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2026-06-09Clinical Trial Results: Low Load Resistance Training Using Blood Flow Restriction for People With Multiple Sclerosis [NA]
Clinical trial results for low-load resistance training with blood flow restriction in people with multiple sclerosis have been completed an…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Results: Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals [Phase 1]
Phase 1 single and multiple ascending dose study of MTR-601 in healthy individuals with results posted after completion.
-
CLINICAL_TRIALS trial_result · 2026-04-29Clinical Trial Update: Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis [Phase 3]
Phase 3 trial update comparing Ofatumumab and Siponimod to Fingolimod in pediatric multiple sclerosis for efficacy and safety.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Clinical Investigation to Validate the Safety and Performance of Integrating Functional Electrical Stimulation Into the ABLE Exoskeleton [NA]
A clinical investigation is evaluating the safety and performance of integrating Functional Electrical Stimulation with the ABLE Exoskeleton…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
A National Institute of Allergy and Infectious Diseases-sponsored clinical study is currently recruiting, aiming to conduct comprehensive mu…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: "Evaluation of Usability and Safety of the Self-balancing Walking System Atalante in Patients With Multiple Sclerosis" [NA]
Completed clinical trial evaluating usability and safety of the Atalante self-balancing walking system in people with Multiple Sclerosis, in…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: Supporting Mental Health in Daily Life After the Diagnosis of Multiple Sclerosis
This completed clinical trial examined strategies to support mental health in daily life after a diagnosis of Multiple Sclerosis.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) [Phase 2]
A Phase 2 trial evaluating RO7268489 as add-on therapy to ocrelizumab in participants with progressive multiple sclerosis is currently recru…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Exercise Training for People With Advanced Multiple Sclerosis [NA]
Clinical trial update for an exercise training study in people with advanced multiple sclerosis, sponsored by the University of Ottawa; the …
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Caregiver Burden in Caregivers of Patients With Multiple Sclerosis
A recruiting clinical trial in Istanbul is examining caregiver burden in caregivers of patients with multiple sclerosis.